Literature DB >> 12807432

Tumour necrosis factor-related apoptosis-inducing ligand sequentially activates pro-survival and pro-apoptotic pathways in SK-N-MC neuronal cells.

Daniela Milani1, Giorgio Zauli, Erika Rimondi, Claudio Celeghini, Sandra Marmiroli, Paola Narducci, Silvano Capitani, Paola Secchiero.   

Abstract

The SK-N-MC neuroblastoma cell line, which expresses surface tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) receptors TRAIL-R2 and TRAIL-R4, was used as a model system to examine the effect of TRAIL on key intracellular pathways involved in the control of neuronal cell survival and apoptosis. TRAIL induced distinct short-term (1-60 min) and long-term (3-24 h) effects on the protein kinase B (PKB)/Akt (Akt), extracellular signal-regulated kinase (ERK), cAMP response element-binding protein (CREB), nuclear factor kappa B (NF-kappaB) and caspase pathways. TRAIL rapidly (from 20 min) induced the phosphorylation of Akt and ERK, but not of c-Jun NH2-terminal kinase (JNK). Moreover, TRAIL increased CREB phosphorylation and phospho-CREB DNA binding activity in a phosphatidylinositol 3-kinase (PI 3K)/Akt-dependent manner. At later time points (from 3 to 6 h onwards) TRAIL induced a progressive degradation of inhibitor of kappaB (IkappaB)beta and IkappaBepsilon, but not IkappaBalpha, coupled to the nuclear translocation of NF-kappaB and an increase in its DNA binding activity. In the same time frame, TRAIL started to activate caspase-8 and caspase-3, and to induce apoptosis. Remarkably, caspase-dependent cleavage of NF-kappaB family members as well as of Akt and CREB proteins, but not of ERK, became prominent at 24 h, a time point coincident with the peak of caspase-dependent apoptosis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12807432     DOI: 10.1046/j.1471-4159.2003.01805.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  26 in total

1.  The negative prognostic value of TRAIL overexpression in oral squamous cell carcinomas does not preclude the potential therapeutic use of recombinant TRAIL.

Authors:  Francesco Carinci; Lorenzo Monasta; Corrado Rubini; Daniela Stramazzotti; Annalisa Palmieri; Elisabetta Melloni; Alex Knowles; Luca Ronfani; Giorgio Zauli; Paola Secchiero
Journal:  Invest New Drugs       Date:  2010-11-18       Impact factor: 3.850

2.  TRAIL shows potential cardioprotective activity.

Authors:  Barbara Toffoli; Stella Bernardi; Riccardo Candido; Serena Zacchigna; Bruno Fabris; Paola Secchiero
Journal:  Invest New Drugs       Date:  2011-01-04       Impact factor: 3.850

3.  Multiple effects of TRAIL in human carcinoma cells: induction of apoptosis, senescence, proliferation, and cytokine production.

Authors:  Vera Levina; Adele M Marrangoni; Richard DeMarco; Elieser Gorelik; Anna E Lokshin
Journal:  Exp Cell Res       Date:  2008-01-16       Impact factor: 3.905

4.  Tumor necrosis factor alpha is reparative via TNFR2 [corrected] in the hippocampus and via TNFR1 [corrected] in the striatum after virus-induced encephalitis.

Authors:  Moses Rodriguez; Laurie Zoecklein; Louisa Papke; Jeff Gamez; Aleksandar Denic; Slobodan Macura; Charles Howe
Journal:  Brain Pathol       Date:  2008-04-15       Impact factor: 6.508

5.  Nutlin-3 differentially modulates miRNA34a and miRNA181 versus miR26a and miR155 in p53 proficient and p53 deficient B chronic lymphocytic leukemia (B-CLL) samples.

Authors:  Maria Grazia di Iasio; Riccardo Addobbati; Oriano Radillo; Rebecca Voltan
Journal:  Invest New Drugs       Date:  2011-05-31       Impact factor: 3.850

Review 6.  TNF receptor 2 pathway: drug target for autoimmune diseases.

Authors:  Denise Faustman; Miriam Davis
Journal:  Nat Rev Drug Discov       Date:  2010-05-21       Impact factor: 84.694

Review 7.  Targeting TNF-related apoptosis-inducing ligand (TRAIL) receptor by natural products as a potential therapeutic approach for cancer therapy.

Authors:  Xiaoyun Dai; Jingwen Zhang; Frank Arfuso; Arunachalam Chinnathambi; M E Zayed; Sulaiman Ali Alharbi; Alan Prem Kumar; Kwang Seok Ahn; Gautam Sethi
Journal:  Exp Biol Med (Maywood)       Date:  2015-04-07

8.  Treatment with recombinant tumor necrosis factor-related apoptosis-inducing ligand alleviates the severity of streptozotocin-induced diabetes.

Authors:  Giorgio Zauli; Barbara Toffoli; Maria Grazia di Iasio; Claudio Celeghini; Bruno Fabris; Paola Secchiero
Journal:  Diabetes       Date:  2010-02-25       Impact factor: 9.461

9.  Soluble TRAIL in normal pregnancy and acute pyelonephritis: a potential explanation for the susceptibility of pregnant women to microbial products and infection.

Authors:  Piya Chaemsaithong; Roberto Romero; Steven J Korzeniewski; Alyse G Schwartz; Tamara Stampalija; Zhong Dong; Lami Yeo; Edgar Hernandez-Andrade; Sonia S Hassan; Tinnakorn Chaiworapongsa
Journal:  J Matern Fetal Neonatal Med       Date:  2013-04-22

10.  TRAIL activates a caspase 9/7-dependent pathway in caspase 8/10-defective SK-N-SH neuroblastoma cells with two functional end points: induction of apoptosis and PGE2 release.

Authors:  Giorgio Zauli; Daniela Milani; Erika Rimondi; Giovanna Baldini; Vanessa Nicolin; Vittorio Grill; Paola Secchiero
Journal:  Neoplasia       Date:  2003 Sep-Oct       Impact factor: 5.715

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.